ICER issues final report for hATTR therapies with recommendations

ICER released its final evidence report on treatments for hereditary transthyretin (TTR)-mediated amyloidosis (hATTR) recommending that insurers and payers develop prior authorization criteria for Onpattro patisiran and Tegsedi inotersen, and that manufacturers bring prices

Read the full 340 word article

User Sign In